DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells
Ruocong Zhao(Chinese Academy of Sciences), Peng Li(Chinese Academy of Sciences), Duanqing Pei(Westlake University), Shuzhong Cui(Guangzhou Medical University), Youguo Long(Chinese Academy of Sciences), Qiting Wu(Chinese Academy of Sciences), Yangqiu Li(Jinan University), Zhiwu Jiang(Guangxi University), Yao Yao(Dalian Medical University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Simiao Lin(Chinese Academy of Sciences), Xin Du(Changchun University of Science and Technology), Lin Cheng(Chinese Academy of Sciences), Suna Wang(National Institutes of Health), Xinru Wei(China Energy Engineering Corporation (China)), Pentao Liu(Hong Kong Science and Technology Parks Corporation), Xuchao Zhang(Guangdong General Hospital), Baiheng Li(Chinese Academy of Sciences)
Cited by 35
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k